Clinical trial

Abbreviated Post-partum Magnesium Sulfate Seizure Prophylaxis in Preeclampsia: A Comparison of 12 and 24 Hour Regimens

Name
IRB 01001-OBG-01
Description
Magnesium sulfate is used for seizure prophylaxis in pregnancies complicated by preeclampsia. There is debate as to how long to continue this therapy after delivery of the pregnancy. Different schemes have been offered to shorten the exposure to magnesium sulfate after delivery, with little data. We seek to investigate the effect of shortened magnesium sulfate therapy on the post-partum recovery phase of mild preeclampsia. Our hypothesis was that shortened therapy (12 hours versus the traditional 24 hours post-partum) has no effect on disease course, and will result in significantly shorter exposure to magnesium sulfate.
Trial arms
Trial start
2001-01-01
Trial end
2004-08-01
Status
Completed
Treatment
abbreviation of magnesium sulfate therapy (12 hours versus the traditional 24 hours after delivery)
Size
200
Primary endpoint
Time of magnesium sulfate therapy (minutes)
Blood pressure
Maternal symptoms (headaches, blurred vision, chest pain, shortness of breath)
Eligibility criteria
Inclusion Criteria: * Women with suspected mild preeclampsia diagnosed antepartum, intrapartum, or post-partum were eligible for inclusion after delivery at term (≥ 34 weeks' gestational age). Exclusion Criteria: * Inability to give informed consent, preterm delivery, severe preeclampsia
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 200}}
Updated at
2023-11-01

1 organization

1 product

2 indications

Indication
Pregnancy
Indication
Preeclampsia